MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

Search

Vaxcyte Inc

Închisă

SectorSănătate

35.34 -2.78

Rezumat

Modificarea prețului

24h

Curent

Minim

34.8

Maxim

36.65

Indicatori cheie

By Trading Economics

Venit

-3.6M

-141M

Angajați

414

EBITDA

-123M

-176M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+162.32% upside

Dividende

By Dow Jones

Următoarele câștiguri

4 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-276M

4.3B

Deschiderea anterioară

38.12

Închiderea anterioară

35.34

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Vaxcyte Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

31 mar. 2025, 14:19 UTC

Principalele dinamici ale pieței

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

3 sept. 2024, 17:22 UTC

Top știri

Pfizer Better Watch Out for This Biotech -- Heard on the Street-- WSJ

Comparație

Modificare preț

Vaxcyte Inc Așteptări

Obiectiv de preț

By TipRanks

162.32% sus

Prognoză pe 12 luni

Medie 94.25 USD  162.32%

Maxim 137 USD

Minim 65 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVaxcyte Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

6

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

28.09 / 34Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.